Drug intelligence / Profile preview

IVIEW-3002

Development stage: Preclinical
Lead developer: IVIEW Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

IVIEW-3002 is an investigational small molecule therapeutic candidate being developed by iVIEW Therapeutics (also known as IVIEW Pharmaceutical) for the treatment of wet age-related macular degeneration (wet AMD). The drug is designed for localized delivery to the eye via eyelid periorbital administration, offering a non-invasive alternative to traditional intravitreal injections. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on IVIEW-3002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVIEW-3002.

Explore the full profile